ARCHIVES

NCI To Fund Only 30-35% Of Approved Grants Even With $815 Million Construction Slashed

This article is from The Cancer Letter archive.

Vol. 02 No. 34 | August 20, 1976

Download PDF Visit The Full Archive

Related Articles

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

April 1, 2005

Pancreatic Cancer Pain Reduction Concept Approved

May 23, 1986

In Brief: FDA Advisors Ask Cetus To Refine IL-2 Application; NIH Reauthorization Introduced

August 3, 1990

CCIRC Told Group Radiation Studies Cost $20,000 Per 25 Patients

March 14, 1980

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

July 31, 2009

Medicare Program: HCFA Expands Coverage Of Cancer Screening Methods

January 9, 1998